PM-3002

N/A

Report date: 2022/03/28 14:12:00

Base Information

Drug NamePM-3002
Drug Alias NamePM-3002
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy
Mechanisms of ActionReceptor protein-tyrosine kinase erbB-2 modulators
TargetsReceptor protein-tyrosine kinase erbB-2
Therapy Area/IndicationsN/A
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator Companies +[1]  N/A
China Registration ClassN/A

Develop Information

Active CompaniesSuzhou Aika Liyuan Biotechnology Co Ltd +[2] 
Inactive CompaniesN/A
Active IndicationsN/A
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A